Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity (Parenthetical)

v2.4.0.6
Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Tax benefit/expense associated with change in fair value of interest rate swap agreements $ 1,527 $ (2,247) $ (7,045)
Tax expense associated with discontinuance of cash flow swaps     1,711
Tax benefit related to the derecognition of equity component of 4.25% and 5.0% convertible notes in 2009 and 2011 respectively 627   2,887
Tax expense related to recognition of equity component of 5% convertible notes     12,823
Dividends per share $ 0.10 $ 0.025  
Tax benefit associated with change in pension actuarial loss 193    
Paid-In Capital
      
Tax benefit related to the derecognition of equity component of 4.25% and 5.0% convertible notes in 2009 and 2011 respectively 627   2,887
Tax expense related to recognition of equity component of 5% convertible notes     12,823
Retained Earnings / (Accumulated Deficit)
      
Dividends per share $ 0.10 $ 0.025  
Accumulated Other Comprehensive Income (Loss)
      
Tax benefit/expense associated with change in fair value of interest rate swap agreements 1,527 (2,247) (7,045)
Tax expense associated with discontinuance of cash flow swaps     1,711
Tax benefit associated with change in pension actuarial loss $ 193